To keep drug prices high, pharma has been piling up the patents
60-Word AI Digest
To keep drug prices high, pharma has been piling up the patents. Reporting by Ars Technica highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.
Key Takeaways
- To keep drug prices high, pharma has been piling up the patents
- Add-on patents have increased drug patent periods from two years to over six.
- Click full coverage link below for the complete official dispatch.
Add-on patents have increased drug patent periods from two years to over six.
Original Publisher Attribution
This summary was curated from Ars Technica.